Please assess the completion status of the following clinical trial:

Trial Title: TELICAST : Telithromycin in Acute Exacerbations of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~Patients meeting all of the following criteria will be considered for enrollment in the study:~* A documented history of asthma for \>6 months~* Presenting within 24 hours of initial medical care in an urgent care clinic, emergency room, or in-patient hospital setting. To qualify for enrollment they must present with the following signs and symptoms of an acute deterioration in asthma control: (reduced PEFR, increased wheeze, and dyspnea, with or without cough).~* A PEFR less than 80% of predicted normal~* Females who meet the following conditions:~  * postmenopausal for at least 1 year, or~ * surgically incapable of bearing children, or~ * of childbearing potential, and all of the following conditions are met:~    * had a normal menstrual flow within 1 month before study entry and~   * has a negative pregnancy test (serum b-subunit human chorionic gonadotropin \[hCG\]) immediately before study entry and~   * must agree to abstinence or use of an accepted method of contraception~Exclusion criteria~Patients presenting with any of the following will not be included in the study:~* Requiring immediate placement in an Intensive Care Unit~* Obvious known allergic precipitant for this episode of acute severe asthma (e.g., acute exposure to animal dander)~* Pneumonia~* Known long QT syndrome or familial history of long QT syndrome (if no previous electrocardiogram \[ECG\] has invalidated this risk factor), or personal history of coronary disease, ventricular arrhythmia, bradycardia \<50 beats/min, or known uncorrected hypokalemia or magnesemia~* Known impaired hepatic or renal function~* Known diagnosis of myasthenia gravis~* Active or quiescent tuberculosis infections of the respiratory tract~* Acute exacerbation of chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, or emphysema~* A history of smoking of 10 pack-years or more~* Women who are breast feeding or are pregnant, as demonstrated by serum or urine pregnancy tests~* Suspected or known hypersensitivity to, or suspected serious adverse reaction to the macrolide class of antibiotics~* A concomitant condition (including clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease) that would make implementation of the protocol or interpretation of the study results difficult~* A recent (within the previous 3 months) history of alcohol or recreational drug misuse.~* Immunocompromised patients, including but not limited to:~  * patients with known human immunodeficiency virus (HIV) infection and have either had or have an AIDS defining condition (e.g., Kaposi's sarcoma, Pneumocystis carinii pneumonia) or a CD4 + T lymphocyte count of \<200/mL~ * patients with neutropenia (\<1500 neutrophils/mm3)~ * patients with metastatic or hematological malignancy~ * splenectomized patients or patients with known hyposplenia or asplenia~* Planned surgical treatment at any time during the course of the study that would be incompatible with the objectives of this study~* Other disease conditions or infections that could interfere with the evaluation of study treatment efficacy or safety~* Oral steroid-dependent asthma~* Antibiotic use within 30 days prior to enrollment~* Treated within 2 weeks prior to inclusion with CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, and St. John's Wart~* Currently receiving medication known to prolong QT interval such as cisapride, pimozide, astemizole and terfenadine, or potent CYP3A4 inhibitors such as antiproteases or ketoconazole.~* Patients in whom an antibiotic is clearly indicated.~* Have received treatment with any other investigational drug within 1 month prior to study entry, or have such treatment planned for the study period during treatment and follow-up phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).